Asset profile

Durvalumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(59 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (7)

September 2026 (3)

Phase 2Intrahepatic Cholangiocarcinoma (Icc), HAIC, DurvalumabRecruiting

Est. primary completion 2026-09-06 · NCT06859684 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8 …Recruiting

Est. primary completion 2026-09-30 · NCT04892953 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-09-30 · NCT05221840 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2026 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-10-23 · NCT06008093 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (3)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-12 · NCT05000710 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRDRecruiting

Est. primary completion 2026-12 · NCT03740893 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaRecruiting

Est. primary completion 2026-12-30 · NCT03606967 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (18)

January 2027 (2)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-01 · NCT05206812 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung CancerActive not recruiting

Est. primary completion 2027-01-18 · NCT05374603 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (4)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT05696782 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-02 · NCT04716946 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT04499053 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-05 · NCT03694236 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-05-19 · NCT06424899 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-06 · NCT05742607 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8Recruiting

Est. primary completion 2027-06-30 · NCT05198830 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (2)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-07 · NCT03999710 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Breast CancerRecruiting

Est. primary completion 2027-07-28 · NCT06103864 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-08-31 · NCT04465968 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (1)

Phase 3Breast CancerActive not recruiting

Est. primary completion 2027-09-20 · NCT05629585 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 1/2Colorectal Neoplasms, Breast NeoplasmsActive not recruiting

Est. primary completion 2027-10-30 · NCT02484404 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-11-01 · NCT05687266 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (2)

Phase 2Triple Negative Breast Cancer MetastaticRecruiting

Est. primary completion 2027-12 · NCT05582538 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast CancerRecruiting

Est. primary completion 2027-12-01 · NCT05795101 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (17)

January 2028 (1)

Phase 2Adenocarcinoma of Lung, Lung CancerRecruiting

Est. primary completion 2028-01 · NCT04105270 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2028 (1)

Phase 2Triple Negative Breast CancerRecruiting

Est. primary completion 2028-02 · NCT06954480 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-03-01 · NCT07653438 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-04 · NCT07146230 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 2Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node InvolvementRecruiting

Est. primary completion 2028-05-15 · NCT07063888 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-06 · NCT06680050 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8Active not recruiting

Est. primary completion 2028-06-30 · NCT06732401 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2028 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-07-12 · NCT05211895 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (2)

Phase 2Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8Recruiting

Est. primary completion 2028-10-08 · NCT07288034 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-10-31 · NCT03833154 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2028 (2)

Phase 3Breast CancerActive not recruiting

Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-11-30 · NCT01993810 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (5)

Phase 3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-12 · NCT04597671 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-31 · NCT07632365 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-12-31 · NCT06667908 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8 …Active not recruiting

Est. primary completion 2028-12-31 · NCT04092283 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (7)

May 2029 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-05 · NCT06890598 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)

Phase 3Small Cell Lung CarcinomaActive not recruiting

Est. primary completion 2029-06-30 · NCT06992609 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2029 (2)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-10 · NCT06284317 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer …Recruiting

Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-12-31 · NCT06810609 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2029-12-31 · NCT07560358 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (5)

March 2030 (1)

Phase 3Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2030-03 · NCT06858410 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2030 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-06-25 · NCT07603856 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2030 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2030-11 · NCT07759492 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting

Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (2)

October 2031 (1)

Phase 3Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8Recruiting

Est. primary completion 2031-10-15 · NCT05624996 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2031 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2031-12-30 · NCT07247786 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (2)

May 2032 (1)

Phase 3Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma …Recruiting

Est. primary completion 2032-05-31 · NCT06058377 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2032 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2032-12-15 · NCT07554339 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2039 (1)

July 2039 (1)

Phase 3Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8Recruiting

Est. primary completion 2039-07-15 · NCT06498635 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.